EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS: Case 4

Video

EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS

Riess case 4:

52-year-old man with relapsed metastatic NSCLC.

  • 52-year-old man developed NSCLC, metastatic to the bone and brain
  • Was found to have an EGFR activating mutation
  • Started on erlotinib with a good response, received radiotherapy to hip and brain
  • After 12 months he developed cough and dyspnea on exertion
  • CT scan showed progression in the primary lesion and multiple other pulmonary nodules
  • Tissue biopsy showed an EGFR T790M mutation
  • Subsequent treatment with osimertinib resulted in tumor shrinkage as well as resolution of his symptoms.
Related Videos
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Prithviraj Bose, MD, an expert on myelofibrosis
Prithviraj Bose, MD, an expert on myelofibrosis
Related Content
Treating Rare Driver Mutations in NSCLC: EGFR Exon 20 Insertions

Treating Rare Driver Mutations in NSCLC: EGFR Exon 20 Insertions

April 24th 2024
Article

During a Case-Based Roundtable® event, Misako Nagasaka, MD, discussed treatment for a patient with non–small cell lung cancer and an EGFR exon 20 insertion.

Read More

FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

March 15th 2024
Podcast

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

Listen

FDA Approves Adjuvant Alectinib in ALK+ NSCLC

FDA Approves Adjuvant Alectinib in ALK+ NSCLC

April 18th 2024
Article

The FDA approved adjuvant alectinib following tumor resection for the treatment of patients with ALK-positive non-small cell lung cancer.

Read More

Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care

Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care

December 15th 2023
Podcast

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Listen

Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer

Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer

April 15th 2024
Article

Aaron Lisberg, MD, discussed the phase 3 TROPION-Lung01 study which evaluated datopotamab deruxtecan for patients with advanced or metastatic non-small cell lung cancer.

Read More

Evolving Treatment Paradigms with Amivantamab in Wild-Type NSCLC

Evolving Treatment Paradigms with Amivantamab in Wild-Type NSCLC

April 12th 2024
Article

Natasha Leighl, MD, MMSc, BSc, discussed the analysis of the CHRYSALIS study that was presented at the 2024 American Association for Cancer Research Annual Meeting.

Read More